Clinical trial
A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
NCT03578146 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Vehicle-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers
- Lead sponsor
- Portola Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2012
- Completion date
- September 30, 2015
- Enrollment
- 48 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
healthy volunteers